Claims for Patent: 5,225,354

Summary for Patent: 5,225,354

Title:	Monoclonal antibodies specific for human glycoalbumin
Abstract:	Monoclonal antibodies specific for the glycosylated lysine residue at position 525 in glycoalbumin and a method for producing such antibodies. The monoclonal antibodies are useful as reagents in immunoassays for the specific determination of glycoalbumin in human blood samples which is indicative of the severity of the diabetic condition. The monoclonal antibodies are secreted by hybridomas obtained by fusing a myeloma cell with a lymphocyte that has been taken from an animal, usually a mouse, immunized with a peptide immunogen and which produces antibody to the lysine 525 residue in glycoalbumin. The synthetic peptide immunogen comprises a peptide residue which includes an .epsilon.-amino glucosylated lysine and an adjacent amino acid sequence in which at least one of the amino acid units is in a position corresponding to the peptide sequence of human albumin adjacent to lysine 525, the glycosylated peptide residue being linked to an immunogenic carrier.
Inventor(s):	Knowles; William J. (Madison, CT), Marchesi; Vincent T. (Guilford, CT)
Assignee:	Molecular Diagnostics, Inc. (West Haven, CT)
Application Number:	07/934,085
Patent Claims:	1. An immunoassay method for determining glycosylated albumin in a human blood sample, comprising the steps of: (a) contacting the blood sample with a monoclonal antibody, or a fragment thereof comprising an antibody combining site, which binds specifically to human albumin at lysine residue 525, wherein said lysine residue is glycosylated, and wherein said monoclonal antibody does not bind substantially to any other proteins present in human blood; and (b) determining binding of said monoclonal antibody or fragment thereof to glycosylated human albumin as a function of the amount of glycosylated albumin in the sample tested. 2. The method of claim 1, wherein the blood sample is pretreated to denature a significant amount of any glycosylated albumin therein. 3. The method of claim 1, wherein the monoclonal antibody or fragment thereof binds specifically to a glycosylated peptide residue of the formula: ##STR13## wherein Glyco-(NH) represents a nonenzymatically glycosylated .epsilon.-amino group in the lysine residue, and one or both of AA.sub.1 and AA.sub.2 is a sequence of amino acids wherein at least one of the amino acid units is in a position corresponding to the peptide sequence of human albumin adjacent to the lysine residue at position 525, and if only one of AA.sub.1 and AA.sub.2 is such a sequence, then the other is a bond or additional amino acid residues. 4. The method of claim 3, wherein one or both of AA.sub.1 and AA.sub.2 is a sequence of from 1 to 12 amino acids corresponding to the peptide sequence adjacent to the lysine residue at position 525 in human albumin. 5. The method of claim 1, wherein the monoclonal antibody has been raised against an immunogen comprising a glycosylated peptide chemically linked to an immunogenic carrier material, the glycosylated peptide comprising a lysine residue whose .epsilon.-amino group is nonenzymatically glycosylated and at least one other amino acid unit in a position corresponding to the peptide sequence of human albumin adjacent to the lysine residue at position 525. 6. The method of claim 5, wherein the immunogen is of the formula: ##STR14## wherein Glyco-(NH) represents a nonenzymatically glycosylated .epsilon.-amino group in the lysine residue; one or both of AA.sub.1 and AA.sub.2 is a sequence of amino acids wherein at least one of the amino acid units is in a position corresponding to the peptide sequence of human albumin adjacent to the lysine residue at position 525, and if only one of AA.sub.1 and AA.sub.2 is such a sequence, then the other is a bond, a terminal amino or carboxyl group, or additional amino acid residues; R is a bond or linking group; Carrier is an immunogenic carrier material; one of m and n is 1 and the other is zero; and p is on the average from 1 to the number of available coupling sites on Carrier. 7. The method of claim 6, wherein AA.sub.1 is a terminal amino group, AA.sub.2 is Gln-Thr-Ala-Leu-Val-Glu-Leu-Val-Lys, m is zero, and n is 1. 8. The method of claim 6, wherein AA.sub.1 is (NH.sub.2)Arg-Gln-Ile-Lys, AA.sub.2 is Gln-Thr-Ala-Leu-Val-Glu, m is zero, and n is 1. 9. The method of claim 6, wherein AA.sub.1 is (NH.sub.2)Lys-Glu-Arg-Gln-Ile-Lys and AA.sub.2 is Gln-Thr-Ala-Leu-Val-Tyr-Cys wherein Lys is a glucosylated or non-glycosylated lysine unit, and wherein m is zero and n is 1. 10. The method of claim 6, wherein AA.sub.1 is Cys-Glu-Arg-Gln-Ile-Lys and AA.sub.2 is Gln-Thr-Ala-Leu (COOH) wherein Lys is a glycosylated or non-glycosylated lysine unit, and m is 1 and n is zero. 11. The method of claim 6, wherein AA.sub.1 is Gln-Ile-Lys, Ile-Lys, Lys, or a terminal amino group; AA.sub.2 is Gln-Thr-Ala-Leu-Tyr-Tyr-Cys; m is zero, and n is 1. 12. The method of claim 11, wherein AA.sub.1 is Gln-Ile-Lys. 13. The method of claim 4, wherein AA.sub.1 is Cys-Tyr-Tyr-Arg-Gln-Ile-Lys; AA.sub.2 is Gln-Thr, m is 1 and n is zero. 14. The method of claim 11, wherein the blood sample is whole blood, serum or plasma.

Details for Patent 5,225,354

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Grifols Therapeutics Llc	ALBUKED, PLASBUMIN-20, PLASBUMIN-25, PLASBUMIN-5	albumin (human)	For Injection	101138	10/21/1942		2010-07-06
Baxalta Us Inc.	BUMINATE, FLEXBUMIN	albumin (human)	Injection	101452	03/03/1954		2010-07-06
Csl Behring Ag	ALBURX	albumin (human)	Injection	102366	07/23/1976		2010-07-06
Grifols Biologicals Llc	ALBUTEIN	albumin (human)	Injection	102478	08/15/1978		2010-07-06